pT3N0M0期胸段食管鳞癌根治术后的预后因素
DOI: 10.3971/j.issn.1000-8578.2016.06.010
Keywords: Partial Versus Radical Nephrectomy,Relationship of Macrophage Migration Inhibitory Factor Expression with Clinicopathologic Features and Prognosis of Cardiac Carcinoma Patients,Advance of Prognostic Markers of Cervical Cancer,Correlation of CD68+ Tumor-associated Macrophages Number with Ki-67 Expression and Prognosis of Patients with Primary Hepatocellular Carcinoma,Prognostic Value of Circulating Tumor Cells for Metastatic Prostate Cancer: A Metaanalysis,Metaplastic Carcinoma of Breast with Mesenchymal Differentiation: 28 Cases Report,Predictive Value of C-reactive Protein/Albumin Ratio on Prognosis of Patients with Primary Hepatocellular Carcinoma,Clinical Investigation on Qingfei Mixture Combined with Chemotherapy on Middle and Advanced Non-small Cell Lung Cancer,Expression and Clinical Significance of Artemin Protein in Triple-negative and Nontriple-negative Breast Cancer Tissues,Value of 21-gene Assay in Treatment Decisions for Hormone Receptor-positive Nodepositive Early Breast Cancer,Clinical Characteristics and Prognosis of 123 Patients with Diffuse Large B-cell Lymphoma of Waldeyer’s Ring
Abstract:
摘要 目的 探讨pT3N0M0期胸段食管鳞癌两野根治术后的预后及其影响因素。方法 胸段食管鳞癌行胸腹两野食管癌根治术后、分期为pT3N0M0者249例，中位年龄60岁（33~78岁）；胸上段39例、胸中段166例、胸下段44例，病变中位长度5 cm（2~12 cm）；术中无粘连者35例、轻度粘连者90例、重度粘连者124例；术中清扫淋巴结中位数9枚（1~27枚）；98例单纯手术、151例行术后辅助治疗。结果 249例中1、3、5年总生存率（overall Survival, OS）和无进展生存率（progression-free survival, PFS）分别为90.0%、68.7%、55.2%和82.1%、61.7%、5 3 . 9%。单因素分析结果显示：性别、肿瘤位置、病理分化程度和术前血红蛋白水平与O S 有关（P<0.05）；年龄、肿瘤位置和术中粘连程度与PFS有关（P<0.05）；多因素分析结果显示：肿瘤位置、术前血红蛋白水平、术前CT有纵隔小淋巴结（<1 cm）和清扫淋巴结数目是OS独立影响因素，肿瘤位置是影响PFS独立危险因素。术后辅助治疗对OS和PFS均无明显影响；但术前CT纵隔有小淋巴结（<1 cm）者，术后辅助治疗可以提高OS和PFS（P<0.05）。结论 pT3N0M0期胸段食管鳞癌胸腹两野根治术后，肿瘤位置影响OS和PFS，胸下段癌预后最好，胸上段癌预后最差；术中清扫淋巴结数多、术前CT纵隔无淋巴结者预后较好，反之预后较差；术前血红蛋白高者生存率低；而术后辅助治疗的价值有待证实
Full-Text
